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stroma in three-dimensional (3D) tumour models to recapitulate the native tumour microen-
vironment in situ.
Methods: Using a compartmentalised, biomimetic, 3D cancer model, comprising a central
cancer mass surrounded by a vascularised stroma, we have tested the invasive capability of
colorectal cancer cells.
Results: We show histological analysis of dense collagen I/laminin scaffolds, forming necrotic
cores with cellular debris. Furthermore, cancer cells within this 3D matrix form spheroids,
which is corroborated with high EpCAM expression. We validate the invasive growth of can-
cer cells into the stroma through quantitative image analysis and upregulation of known inva-
sive gene markers, including metastasis associated in colon cancer 1, matrix metalloproteinase 7
and heparinase. Tumouroids containing highly invasive HCT116 cancer masses form less
complex and less branched vascular networks, recapitulating ‘leaky’ vasculature associated
with highly metastatic cancers. Angiogenic factors regulating this were vascular endothelial
growth factor A and hepatocyte growth factor active protein. Where vascular networks were
formed with less invasive cancer masses (HT29), higher expression of vascular endothelial cad-
herin active protein resulted in more complex and branched networks. To eliminate the cell
ecell interaction between the cancer mass and stroma, we developed a three-compartment
model containing an acellular ring to test the chemoattractant pull from the cancer mass. This
resulted in migration of endothelial networks through the acellular ring accompanied by(U. Cheema).
Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Discussion: This work interrogates to the gene and protein level how cancer cells influence the
development of a complex stroma, which shows to be directly influenced by the invasive capa-
bility of the cancer.
ª 2019 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Cancer invasion and three-dimensional disease models
Most research studies into cancer cell behaviour and
pathology rely heavily on two-dimensional (2D) mono-
layers of immortalised cancer cell lines. This does not
recapitulate the complex cell-to-cell communication of
cancer and stromal cells, the influence of extracellular
matrix components and the spatial configuration that
promotes cancer growth and metastasis of especially
colorectal cancer (CRC) [1,2]. Increasingly, the focus
has now been to mimic the cancer microenvironment
and macroenvironment to better understand tumour
growth. One approach has been to use spheroids of
cancer cells grown on low-attachment tissue culture
plates. Although this formation enables cancer cells to
communicate with one another and starts to form a
‘mass’ by releasing low levels of inherent collagen [3],
significant aspects of the tumour environment are still
missing. It is for this reason that more complex models
using biological scaffolds such as Matrigel and
collagen are used to create an extracellular matrix to
achieve biomimicry and study cancer disease pathways
by recreating the tumour microenvironment especially.
Patient-derived xenograft (PDx) models are a strong
tool for preclinical in vivo models of cancer, especially
when orthotopically transplanted. However, a major
limitation of PDx models is that the tumour microen-
vironment cannot be recreated owing to important
stromal cells such as cancer-associated fibroblasts and
endothelial cells not being explanted with the tumour
sample [4]. In addition, the adaptive immune component
of cancer resistance cannot accurately be modelled [5].
Novel three-dimensional (3D) models of cancer using a
collagen matrix are able to include these components to
enable the cancer-stromal cell crosstalk, therefore being
able to fill this gap in the biomimicry of cancer disease
models.
Progression and metastasis of CRC is a disease pro-
cess that is understood to originate by gastrointestinal
epithelial cells within a healthy tissue that undergo the
epithelial-to-mesenchymal transition (EMT). EMT en-
ables cells to migrate to different sites, where once
reached, they will revert to an epithelial phenotype,
undergoing the so-far minimally researched
mesenchymal-to-epithelial transition (MET) to form a
new stable colonisation of cancer cells [6]. There are a
number of hypotheses on what causes this initial EMTin CRC, including prolonged inflammation causing
elevated levels of interleukin-6 [7] and eventually the
induction of the EMT transcription factor SNAIL [8].
This process is often furthered by the upregulation of E-
cadherin, which will maintain the metastases especially
in the lungs after the MET [2]. The initial ‘budding’ of
cell clusters or spheroids (5 cells) [9] may be initiated
by the loss of E-cadherin [10] and then driven by an
overexpression of matrix metallopeptidase 9 (MMP9) to
break down the surrounding matrix and create a path to
a new source of oxygen and nutrients [11]. The newly
established invasive body will require a number of
factors to survive as a now-independent cluster of cells.
Some genes, such as metastasis associated in colon cancer
1 (MACC1), are crucial markers for metastatic CRC,
thus being a key regulator in the hepatocyte growth
factor (HGF)einduced MET [12], whereas freely
circulating matrix metalloproteinase-7/matrilysin
(MMP7) is associated with distant metastasis in CRC
[13]. Matrix metalloproteinase 2 (MMP2) ‘effectively
identifies the presence of CRC’ and is activated espe-
cially by clustering cells [14]. Furthermore, it has
recently been shown that even circulating tumour cells
recruit and communicate with endothelial cells to form
clusters of tumour-derived endothelial cells [15]. It is
also vital for a metastasis to promote vasculature,
mainly through the disruption and angiogenesis of local
endothelial networks. This remodelling often leads to
highly disorganised and leaky vasculature forming
around the tumour with a reduced surface area-to-vol-
ume ratio and high interstitial pressure [16,17]. While
most tumours form a necrotic and hypoxic core, the
outer ‘leader cells’ of the cancer mass will recruit peri-
vascular support cells for the formation and remodelling
of vessels, leading to a constant crosstalk between can-
cer and stromal cells to promote tumour growth [18].
Throughout this particular piece of work, we tissue
engineered a CRC model using high-density type I
monomeric collagen [19,20], termed as ‘tumouroids’.
The stiffness of these tumouroids has been confirmed
previously with a modulus/MN m2 of approximately
1.5  0.4 in a single compressed collagen gel [21]. They
consisted of a central cancer mass containing either the
highly invasive HCT116 or less invasive HT29
[22,23] cells and were embedded into a stromal
compartment to recapitulate the tumour microenviron-
ment in situ [24]. The stromal compartment in our model
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and stromal cell types can be added accordingly. The
main question and a major component missing from the
current literature is how the original cancer manipulates
its cellular surroundings and matrix to grow and infil-
trate the tumour margin. We hypothesised that cancer
cells invade, unlike controlled proliferation in normal
cells, disrupting local stromal cell networks and inherent
matrices. In addition, we investigated especially the ef-
fect on the surrounding vasculature, without which, no
cell population would be able to succeed in its path.
Finally, we wanted to create a high-throughput model to
quantify tumour growth and the signalling pathway
involved in early invasion of cancer.
2. Materials and methods
2.1. Histology and haemotoxylin and eosin staining
Historical patient samples on file from 1989 were ob-
tained from a Royal Free Hospital tissue bank. Before
processing, the samples were formalin fixed initially
using 10% neutrally buffered formalin (Genta Medical,
York, UK) and then stored within cassettes to be pro-
cessed by the histopathology department at the Royal
National Orthopaedic Hospital, Stanmore, UK. The
samples were then embedded into blocks and sectioned
into 5-mM thick sections. Haemotoxylin and eosin
(H&E) staining was carried out using the Leica Autos-
tainer XL (Wetzlar, Germany). All sections were imaged
using the Zeiss AxioObersver with ApoTome.2 instru-
ment and software (Zeiss, Oberkochen, Germany).
2.2. Cell culture
Human colorectal adenocarcinoma cell lines HT29 and
HCT116 (both ’European collection of authenticated
cell cultures through Sigma-Aldrich, Dorset, UK) were
cultured in Dulbecco’s Modified Eagle Medium
(DMEM) at 1,000 mg/L glucose (Sigma-Aldrich,
Dorset, UK). Human adult donor dermal fibroblasts
(HDFs) (PromoCell, Heidelberg, Germany) were
cultured in 4,500 mg/L DMEM. Human umbilical vein
endothelial cells (HUVECs) were cultured in Endothe-
lial Cell Growth Medium (both from PromoCell, Hei-
delberg, Germany). Finally, CCD 841 Colon Normal
(CCD 841 CoN) cells were cultured in Minimum
Essential Medium (MEM) supplemented with 1 mM
sodium pyruvate (both from Gibco through Fisher
Scientific, Loughborough, UK). All media were sup-
plemented with 10% foetal calf serum (First Link, Bir-
mingham, UK) in addition to 100 units/mL penicillin
and 100 mg/mL streptomycin (Gibco through Fisher
Scientific, Loughborough, UK). All cell types were
cultured at 5% carbon dioxide (CO2) atmospheric
pressure and at 37 C and passaged regularly in 2Dmonolayers. HDFs and HUVECs were used at passage
5 to avoid differentiation of non-immortalised cell
lines.
2.3. Fabrication of 3D constructs
All 3D constructs were fabricated under sterile con-
ditions, on ice, using monomeric type I rat tail
collagen (First Link, Birmingham, UK) using the
RAFT protocol (Lonza, Slough, UK) as previously
described [24]. This consists of adding 10X MEM
(Sigma-Aldrich, Dorset, UK) to collagen, adding the
corresponding amount of the neutralising agent (17%
10 M NaOH [Sigma-Aldrich, Dorset, UK] in 1 M (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
(HEPES) buffer [Gibco through Thermo Fisher
Scientific, Loughborough, UK]) and finally making up
the volume with a cell medium containing the desired
cell type and number. This results in 80% collagen,
10% 10X MEM, 6% neutralising agent (N.A.) and 4%
cells (8:1:0.6:0.4). For the artificial cancer masses
(ACMs), 50,000 cells/ACM were added to the neu-
tralised collagen gel mix within the corresponding
DMEM volume; and of which, 240 mL was added to a
96-well plate (Corning Costar through Sigma-
Aldrich, Dorset, UK). The gel mix was then left to
cross-link at 37 C for 15 min and subsequently plastic
compressed for 15 min at room temperature using the
96-well RAFT absorbers (Lonza, Slough, UK) to
produce a high-density 3D collagen construct. ACMs
would then be cultured in 200 mL of a cell-type
appropriate medium and cultured at 5%
CO2 atmospheric pressure and 37
C. To produce
‘tumouroids’, the ACMs would be nested into a stro-
mal compartment to recapitulate the tumour micro-
environment appropriately. For the stromal
compartment, the ACMs would be placed into a 24-
well plate (Corning Costar through Sigma-
Aldrich, Dorset, UK) containing 1.3 mL of the
nonecross-linked collagen mix. Extracellular matrix
components could be added to this stromal compart-
ment within the corresponding DMEM volume. In
this case, mouse laminin [25] at 50 mg/mL (0.005% in
hydrogel and 0.24% in plastic compressed) (Corning
through Sigma-Aldrich, Dorset, UK) as well as 25,000
HDFs/sample and 100,000 HUVECs/sample were
added until an acellular stromal compartment was
required. This whole tumouroid would then again be
left to cross-link at 37 C for 15 min and subsequently
plastic compressed using the 24-well RAFT ab-
sorbers for 15 min at room temperature (Lonza,
Slough, UK). These full tumouroids [24] would then
be cultured for up to 21 days in 1.0 mL of cell-
appropriate media (mix 1:1:1 if necessary) at 5%
CO2 atmospheric pressure and 37
C, and every 48 h,
a 50% media change would take place on all
Fig. 1. (A) Schematic of how to make a tumouroid. Adapted using SMART- Servier Medical ART. Two-dimensional monolayers of cells
are used to first make the artificial cancer mass (ACM) in a 96-well plate. The collagen mix achieves a salmon pink colour when neutral pH
is reached. This occurs because of the addition of the neutralising agent containing a strong base because collagen is dissolved in 0.6%
acetic acid. For the ACM, 240 mL of collagen mix containing the desired cell type is pipetted into a 96-well plate. The collagen mix is then
left to cross-link for 15 min at 37C. This will harden the collagen gel. A 96-well plateesized RAFT absorber is then placed on the gel for
15 min, which extracts all the water into the absorbers and increases the collagen density of the hydrogel by a factor of up to 48. The ACM
is then sandwiched into the middle of the stromal compartment by first pipetting half the gel mix into the 24-well plate (650 mL), letting this
set, laying the ACM on this first sandwich half and then pipetting the second half on top (650 mL). The stromal compartment containing
the ACM is then left to set and cross-link completely and then undergoes plastic compression again with a 24-wellesized RAFT
absorber. This results in the complete plastic-compressed tumouroid model, which after experiments, can be used for image analysis, lysed
for RNA extraction or used for media lysate analysis. (B) Fabrication of CRC ‘tumouroids’ using type 1 collagen. Collagen mix for ACMs
was pipetted into a 96-well plate cross-linked and plastic compressed (a). The ACM was then placed into the stromal compartment before
it had set and subsequently set and compressed (b). To measure invasion patterns, the tumouroid was imaged at one focal plane in 4
positions at 10x magnification (c). CRC, colorectal cancer; 3D, three-dimensional.
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of 100e120 mm and collagen concentration of 10%
(compared with 0.2% in hydrogels) as plastic
compression results in a 48-fold increase in collagenconcentration from approximately 2.5 mg/mL to
120 mg/mL [24]. For further technical information on
how to fabricate the tumouroids, please refer to the
detailed schematic in Fig. 1 A and B.
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The constructs were formalin fixed at desired time
points using 10% neutrally buffered formalin (Genta
Medical, York, UK) for 30 min and then washed and
stored in phosphate-buffered saline (PBS) (Gibco
through Fisher Scientific, Loughborough, UK). Before
staining, the constructs were permeabilised and
blocked for 1 h at room temperature using 0.2% Triton
X-100 and 1% bovine serum albumin (BSA) (both from
Sigma-Aldrich, Dorset, UK) dissolved in the same
PBS. Primary antibody incubation was then performed
overnight at 4 C. The secondary antibody incubation
was carried out the next day for 2.5 h at room tem-
perature. Antibodies were diluted in the same Triton
X-100 and BSA solution, and suppliers and source
were as follows: primary 1:200 anti-CK20 rabbit
D9Z1Z (New England Biolabs, Herts, UK), anti-CD31
mouse JC70/A (Abcam, Cambridge, UK), anti-
Vimentin mouse V9 (Santa Cruz, Texas, US) and sec-
ondary 1:1000 anti-mouse Alexa Fluor 488 IgG H&L
ab150113 and anti-rabbit DyLight 594 ab96885 (both
from Abcam, Cambridge, UK). All targets were
counterstained with 40,6-diamidino-2-phenylindole
(DAPI), using NucBlue (Invitrogen through Fisher
Scientific, Loughborough, UK).2.5. Measurement of cancer cell invasion and endothelial
networks
All constructs were imaged using the Zeiss AxioOb-
server with ApoTome.2 feature instrument and software
(Zeiss, Oberkochen, Germany). To measure the
outgrowth (‘invasion’) from the original ACM boarder
into the stromal compartment and orientation of
endothelial structures towards ACMs, 4 images were
taken at a 10x magnification evenly spaced out in
alignment with a clock face at 12, 3, 6 and 9 o’clock on
the same focal plane (see Fig. 1c). This was to randomise
the observations and find a truer average per sample
rather than measure all points of significance. All sam-
ples were assessed for the number of invasive bodies (not
included in main data but can be found in
Supplementary Graph 1) as well as the distance and
cross-sectional surface area of invasion. To analyse the
complexity of the endothelial networks within the sam-
ples, the same image pattern was taken within the
stromal compartment of the tumouroids, and endothe-
lial networks were assessed for number, width and
length (not included in main data but can be found in
Supplementary Graph 2) of branches in addition to the
number of junctions and loops within the networks. The
images obtained were then analysed in Fiji ImageJ
software [26], and the results were analysed using
GraphPad Prism 7 software along with all data obtained
throughout the study.2.6. RNA extraction, cDNA synthesis, qPCR
(quantitative polymerase chain reaction) and enzyme-
linked immunosorbent assay
RNA was extracted using the phase separation TRI
Reagent and chloroform method [27] (both from
Sigma-Aldrich, Dorset, UK). The total RNA obtained
was quantified and tested for integrity using the Nano-
Drop. The RNA was then transcribed into cDNA
using the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems through Fisher Scientific,
Loughborough, UK) on the T100 Thermal Cycler
(Bio-Rad, Watford, UK). Primer pairs for gene target
candidates selected were designed according to the
Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines [28] for
an annealing temperature (Ta) of 60 C, with sequences
shown in Table 1 in the following section, and ordered
through Eurofins Genomics (Ebersberg, Germany).
Primer pair parameters can be found in Supplementary
Information. Gene target amplification was conducted
using the iTaq Universal SYBR Green Supermix on
the CFX96 Touch System (both from Bio-Rad, Wat-
ford, UK) in 10 mL reactions placing 20 ng of sample
cDNA with a primer concentration of 0.2 mM and run
for 40 cycles. Relative gene expression was calculated
using the DCt and 2-DDCt method [29] normalising to the
reference gene hypoxanthine-guanine phosphoribosyl-
transferase (HPRT1) expression, with primer sequences
used as previously described [30]. Media samples from
tumouroids were taken at every 48-h media change,
assessed for PLAU, HGF and vascular endothelial
cadherin (VE-cadherin) active protein expression using
the R&D Systems (Abingdon, UK) Human Magnetic
Luminex assay or Human VE-cadherin Quantikine
enzyme-linked immunosorbent assay kit according to
the manufacturer’s instructions and subsequently read
on the Bio-Rad Bio-Plex MAGPIX Multiplex
Reader (Watford, UK) or the Tecan M200 PRO
Microplate Reader (Ma¨nnedorf, Switzerland).
2.7. Optical projection tomography
Tumouroids were imaged at the UCL Centre for
Advanced Biomedical Imaging. The samples were
formalin fixed using 10% neutrally buffered formalin
(Genta Medical, York, UK) for 30 min and then washed
in PBS (Gibco through Fisher Scientific, Lough-
borough, UK), permeabilised and stained as mentioned
previously with primary 1:200 anti-CK20 rabbit D9Z1Z
(New England Biolabs, Herts, UK) and secondary
1:1000 anti-rabbit Alexa Fluor 568 IgG H&L
ab175473 (both from Abcam, Cambridge, UK) and
embedded in 1% agarose at 37 C after being cut into
quadrants. Dehydration was conducted using 50%, 80%
and 100% ethanol for 24 h each, and replenishment was
carried out with alcohol every 12 h. Finally, the samples
Table 1
Primer pair sequences and efficiency.
Gene Primer F0 Primer R0 Amplicon size (bp) Efficiency (%)
EpCAM TTGCTGTTATTGTGGTTGTGGTG CCCATCTCCTTTATCTCAGCCTTC 112 101
MMP7 ATGAACGCTGGACGGATGGTAG GGGATCTCCATTTCCATAGGTTGG 140 96
MACC1 TACGACTCACAAAGCAACAAATGG AAATCATAGGCAGGTTTCCACATC 100 97
HPSE TAAGACCTTTGGGACCTCATGG CAGATGCAAGCAGCAACTTTGG 193 103
EGFR GGCCGACAGCTATGAGATGGAG AGATCGCCACTGATGGAGGTG 171 98
VEGFA GCCTTGCCTTGCTGCTCTAC GAAGATGTCCACCAGGGTCTCG 155 110
EpCAM, epithelial cell adhesion molecule; MMP7, matrix metallopeptidase; EGFR, epidermal growth factor receptor; VEGFA, vascular endo-
thelial growth factor A; MACC1, metastasis associated in colon cancer 1; HPSE, heparinase.
Primer sequences used for qPCR with amplicon size and efficiency. Pairs were designed according to the MIQE guidelines and optimised for
efficiency.
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benzoate (1:2). The tumouroids were then imaged using
the OPT Scanner 3001M (Bioptonics MRC, Edinburgh,
UK), reconstructed using NRecon (SkyScan, Kontich,
Belgium) and analysed using MATLAB 2017b and
Amira 5.4TM software. Further information can be
found in Supplementary Section.
2.8. Statistical analyses
All statistical analyses were performed using GraphPad
Prism 7 software. Data were tested for normality using
the ShapiroeWilk test (n  3) or the D’Agostino test
(n  8), and then, the appropriate test for statistical
significance was applied depending on the data set and
its parameters. The tests used for each graph are out-
lined within the figure legends. Significance was accepted
at p-values <0.05. All data points are represented as
means with standard error means in graphs, and values,
stated in text as means with standard deviations. In
general, n Z 3 with 3e4 technical replicates, and this is
also further described within the figure legends. F-
values, t-values and degrees of freedom are also noted
within the figure legends for each set of statistical tests.
Two-tailed tests for significance were used for tests
appropriately.
3. Results
3.1. Biomimetic model of cancer with necrotic cores within
spheroid formations
Histological H&E analysis confirmed the similarity in
the cell phenotype between the colorectal tumouroid
model and that observed in patient samples (Fig. 2 A
and B). Necrotic cores within cell clusters were observed
(Fig. 2 B,C and D), a phenomenon identified as ‘dirty
necrosis’ in CRC [31]. The clustering of cells and the
consequent spheroid formation was seen in the less
invasive HT29 ACMs, as well as in the highly invasive
HCT116 [32] ACMs (Fig. 2 F and G); however, the
colon normal cells remained as single cells when
cultured in a 3D collagen matrix (Fig. 2 E). This resultwas underlined by the high expression of the epithelial
cell adhesion molecule (EpCAM), which is responsible
for cell-to-cell connection and overexpressed in tumours
that arise from epithelial tissue [33,34]. When the
mRNA expression of EpCAM was compared between
the three constructs, HT29 and HCT116 containing
tumouroids showed significantly upregulated expression
(both pZ<0.0001) compared with the CCD 841 CoN
normal colon cells.3.2. Invasive growth is a cancer-specific phenomenon
within tumouroids
Clusters of cells grew and migrated from the ACM into
the stromal compartment and formed detached, invasive
bodies (Fig. 3 A,B and C). To validate and term the
outgrowth of cancer cells as ‘invasion’ and not migra-
tion, the invasive CRC gene markers MACC1 [35],
MMP7 [36] and heparinase (HPSE) [37] were measured
within the constructs containing an acellular stromal
compartment at day 21 (Fig. 3 D,E and F). The results
identified that MACC1 was upregulated significantly in
HT29 (pZ<0.0001) and HCT116 (p Z 0.0073)
tumouroids compared with the CCD 841 CoN con-
structs. When comparing MMP7 expression, this gene
was upregulated in the HT29 tumouroids (p Z 0.0007)
compared with the CCD 841 CoN. When comparing the
expression of HPSE, HCT116 tumouroids had a
significantly higher expression (p Z 0.0013) compared
with CCD 841 CoN. The less invasive HT29 tumouroids
invaded from the original ACM into the stromal
compartment in rounded and well-defined cell clusters
resembling tumour ‘budding’ [2] formation with CK20-
positive leader cells [24] at the invading edge (Fig. 3 A,
B, C and G). However, the highly invasive HCT116
tumouroids demonstrate heterogenous CK20 sheet-like
formations when invading into the surrounding stroma
(Fig. 3 H). These HCT116 sheets are not rounded and
show narrower protrusions towards the leading edge
while having frilled edges and no defined boundaries. To
further quantify cancer invasion, the distance of
outgrowth (termed as ‘invasion’) and cross-sectional
surface area were measured over time (Fig. 3 J and
Fig. 2. Histology H&E staining of patient samples with low-grade colon adenocarcinoma (A), high-grade colon adenocarcinoma (B),
HT29 tumouroids (C) and HCT116 tumouroids (D) with scale bar for all images representing 100 mm. Example of 3D morphology of
spheroid-like cluster formation present in colorectal cancer HT29 (E) and HCT116 (F) artificial cancer masses (ACMs) but not when using
colon normal cells (G) CCD 841 CoN in 3D collagen matrix. Pictures taken at day 14 with cytokeratin 20 (CK20; red), DAPI (blue) and
scale bar for all images representing 50 mm. EpCAM (epithelial cell adhesion marker) mRNA levels (H) in ACMs with HT29, HCT116 or
normal colon cells CCD 841 CoN. The value shown is normalised to HPRT1 mRNA levels (mean  SEM) with n Z 3 and 3 technical
repeats. One-way ANOVA with Dunnet’s post hoc test p-values, with the value 0.00005Z ****. H&E, haemotoxylin and eosin; CCD 841
CoN, CCD 841 Colon Normal; 3D, three-dimensional; SEM, standard error mean; ANOVA, analysis of variance.
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further at days 7 (82.47 mm  41.13 mm), 14
(228.5 mm  114.6 mm) and 21 (463.0 mm  207 mm)
compared with HT29 tumouroids at days 7
(39.52 mm  15.09 mm), 14 (90.43 mm  38.23 mm) and21 (110.2 mm  47.70 mm), with the corresponding p-
values for days 7, 14 and 21being pZ<0.0001. For the
cross-sectional surface area, HCT116 tumouroids also
invaded to a significantly greater extent for days 14 and
21 (p < 0.0001), with HT29 cells taking up an average
Fig. 3. Invasive ‘blebbing’ (A), detached bodies formed (B) and overall outgrowth from original ACM (C) observed within HT29
tumouroids with CK20 (red) and DAPI (blue), scale bar Z 50 mm for left and centre images and 500 mm for the right image. Matrix
metalloproteinase 7 (MMP7) (D), metastasis associated in colon cancer 1 (MACC1) (E), heparinase (HPSE) (F) and mRNA levels in
HT29, HCT116 and normal colon cells CCD 841 CoN ACMs embedded into acellular stromal compartments. The value shown is
normalised to HPRT1 mRNA levels (mean  SEM) with nZ 3 and 3 technical repeats. One-way ANOVA with Dunnet’s post hoc test p-
values, with values 0.05Z *, 0.005Z **, 0.0005Z *** and 0.00005Z ****. Images representing invasion of HT29 (G) and HCT116 (H)
cancer cells from ACM into stroma and endothelial structures formed by day 21 with CD31 (green), CK20 (red) and DAPI (blue), scale
bar Z 100 mm. Epidermal growth factor receptor (EGFR) mRNA levels. The value shown is normalised to HPRT1 mRNA levels
(mean  SEM) with n Z 3 and 3 technical repeats (I). T-test p-values, with values 0.05 Z *, 0.005 Z **, 0.0005 Z *** and
0.00005Z ****. Average distance (J) and surface area (K) of invasion measured within tumouroids. Data time points show day 1, 7, 14
and 21 for HT29 and HCT116 tumouroids (mean  SEM) for n Z 3 with 3 technical repeats. ManneWhitney p-values, with values
0.05Z *, 0.005Z **, 0.0005Z *** and 0.00005Z ****. Functional temporal protein expression of PLAU (urokinase) (L) released into
the cell media by tumouroids containing HT29 or HCT116 ACMs. Two-way ANOVA p-values 0.05Z *, 0.005Z **, 0.0005Z *** and
0.00005 Z ****. ACM, artificial cancer mass; SEM, standard error mean; ANOVA, analysis of variance.
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[2] and 26,963 mm [2] 26,871 mm [2] for days 14 and 21,
respectively, and with HCT116 cells, 43,106 mm [2]
42,915 mm [2] and 97,945 mm [2]95,468 mm [2],respectively. This observation is in line with previous in-
group publications by Magdeldin et al. [24]. The highly
invasive nature of HCT116 CRC cells was also
demonstrated by the significant upregulation
Fig. 4. Vascular mimicry, as observed in invasive bodies of HT29 cells (A), with CK20 (red) and DAPI (blue) and scale barZ 50 mm for
both images. Vascular networks in stroma of tumouroids by day 21 containing either HT29 (B) or HCT116 (C) ACMs with CD31 (green)
and DAPI (blue) and scale barZ 100 mm. Complexity was classified by assessing the number of loops (D), number of junctions (E) and
number of branches (F) within the networks (mean  SEM) for n Z 3 showing ManneWhitney p-values, with values 0.05 Z *,
0.005 Z **, 0.0005 Z *** and 0.00005 Z ****. Temporal gene expression changes of VEGFA (G) and CDH5 (VE-cadherin) (H) in
tumouroids containing HT29 or HCT116 ACMs. The value shown is normalised to HPRT1 mRNA levels (mean  SEM) with nZ 3 and
3 technical repeats. Unpaired t-test p-values, with values 0.05Z *, 0.005Z **, 0.0005Z *** and 0.00005Z ****. Functional temporal
protein expression of HGF (H) and VE-cadherin (I) released into the cell media by tumouroids containing HT29 or HCT116 ACMs. Two-
way ANOVA p-values 0.05Z *, 0.005Z **, 0.0005Z *** and 0.00005Z ****. SEM, standard error mean; ACM, artificial cancer mass;
VEGFA, vascular endothelial growth factor A; HGF, hepatocyte growth factor; VE-cadherin, vascular endothelial cadherin; ANOVA,
analysis of variance.
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tor(EGFR) compared with tumouroids containing
HT29 cells (Fig. 3 I). EGFR is highly upregulated in
CRC and has been used as a target for monoclonal
antibody treatment in combination with chemotherapy
[38]. This underlines the fact that the rate of invasion in
a complex vascularised stroma, within our model, is
determined by aggressiveness of the cancer. Another
factor that was significantly upregulated in the HCT116
tumouroids (pZ<0.0001) and released into the media
was the active protein form of urokinase-type plasmin-
ogen activator (PLAU) (Fig. 3 L). This is correlated
with tumour malignancy and is understood to
contribute to tissue degradation to aid metastasis [39].3.3. Vascular complexity is directly affected by cancer
invasion
Within the model, two different levels of vascular
complexity were observed. The cancer responds to
endothelial cells within its proximity, which was seen
through the phenomenon of ‘vascular mimicry’ (Fig. 4
A) in a number of invasive bodies that had budded
from the original ACM into the stromal compartment.
Vascular mimicry, especially in CRC, plays a major
prognostic role [40] and has been used as a predictor
for poor disease outcomes [41]. The endothelial struc-
tures that developed within the stromal compartment
were more complex for the less invasive HT29
Fig. 5. Low-magnification image of HT29 tumouroids showing orientation of endothelial structures towards ACM by day 21 with CK20
(red), CD31 (green) and DAPI (blue), scale bar Z 500 mm (A). The angle of endothelial structures towards the ACMs was measured (B
and C), grouped (mean  SEM) and compared showing KruskaleWallis post hoc Dunn test p-values 0.05Z *, 0.005Z **, 0.0005Z ***
and 0.00005Z ****. Schematic of the acellular ring, where a 48-wellesized acellular collagen ring was placed between the 96-well ACM
and 24-well stromal compartment. (D) Images depicting how endothelial structures travelled through an acellular ring to reach the
HCT116 cancer cells (E), (F) and (G) with CD31 (green) and DAPI (blue), scale bar Z 100 mm. ACM, artificial cancer mass; SEM,
standard error mean.
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HCT116 tumouroids (Fig. 4 B and C). The complexity
of the endothelial networks was assessed (Fig. 4 D,E
and F) by the number of loops, junctions and branches
within the networks. In the presence of HT29 cancer
cells, all complexity measures were statistically signifi-
cantly higher (p Z 0.0002, 0.0093 and 0.0034, respec-
tively) than the HCT116 tumouroids. This points
towards the phenomenon that more aggressive cancers
are more likely to disrupt vasculogenesis and drive
angiogenesis, meaning that the cancer cells interact
with the networks and the networks respond. This was
further investigated by measuring the expression of a
number of genes involved in vasculogenesis and
angiogenesis. No significant difference was found in
genes such as ANG, ANGPT2 or CTNNB1 (see
Supplementary Graph 5). The following genes andproteins showed contrasting differences between the
two CRC cell lines: vascular endothelial growth factor
A (VEGFA) [17], the number one driver of angiogen-
esis, HGF, also a potent angiogenic factor [42], and
VE-cadherin, a major player in vascular junctions and
complexity of networks [43]. VEGFA mRNA levels
(Fig. 4 G) were significantly higher in the HCT116
tumouroids by day 21 (p Z 0.0229) as was the active
HGF protein (Fig. 4 H) released into the media
(p Z 0.0057). The active VE-cadherin protein released
into the tumouroid media was measured and showed
high expression in both groups during early time
points, possibly during the initial formation of endo-
thelial networks (Fig. 4 I). The results confirmed that
over time, the HT29 tumouroids consistently released
significantly more VE-cadherin (p Z 0.006) than the
HCT116 tumouroids.
Fig. 6. OPT-reconstructed image of the HT29 tumouroid (A) with central cancer mass at day 21 with CK20 (orange) and scale
bar Z 3 mm and extracted data showing (B) the number of invasive bodies/cell clusters and (C) total volume of cancer. N Z 1 with 4
quadrants and therefore no statistical analysis.
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model to test chemoattractant gradient
During tumouroid growth, it became clear that endo-
thelial cell structures in the surrounding stroma were
affected by the presence and type of ACM [44]. From
lower magnification images of the ACM and sur-
rounding stroma (Fig. 5 A), it can be seen that the
endothelial structures are oriented radially surrounding
the ACM. This was validated by measuring the angles
of endothelial structures to the ACMs (Fig. 5 B and C),
grouping them into 9 groups of increasing angle size,
with 0 being perfectly perpendicular to the edge of the
ACM. The results showed that by day 21, most endo-
thelial structures had oriented themselves towards the
ACM at an angle of 9 or less. This trend was observed
within the HT29 tumouroids, where by day 21, the
higher proportion of structures fell into the category of
0e9 (39.26%  7.393%). When comparing day 7 with
day 14 and day 21, the results showed that within the
0e9 group, the fraction of endothelial structures was
significantly increased by day 21 (p Z 0.0341).
Furthermore, the same trend was seen for the HCT116
tumouroids, within which by day 21, 41.56%  4.582%
of endothelial structures were within the 0e9 group of
the 9 angle groups. Again, when comparing day 7
values to those of day 14 and day 21, there was a
statistically significant increase by day 21 (p Z 0.0146)
demonstrating that over time, almost 50% endothelial
structures align perpendicular to the cancer. This im-
plies that a chemotactic gradient is created by the
ACM within the construct, which attracts the sur-
rounding endothelial cells. This point was validated by
placing an acellular ring of compressed collagen in
between the ACM and vascularised stromal compart-
ment (Fig. 5D) to test the effect of a chemoattractant
gradient without cell-to-cell interaction. It was
observed that cancer cells and vascular networks
moved towards each other indicating a chemoattractive
gradient between the two compartments (Fig. 5 E,F
and G).3.5. State-of-the-art imaging approach
Optical projection tomography (OPT), a 3D imaging
technology, was used to computationally quantify the
total number of invasive bodies as well as total surface
area and volume to give three binarised values per
quarter (more detail in Supplementary Graph 3) for
HT29 tumouroids (Fig. 6 A). The total number of
invasive bodies (Fig. 6 B) for quadrant 1e4 was
12.33  5.859, 70.67  20.11, 15.00  8.185 and
22.33  3.786. Volume of cancer growth was also
quantified (Fig. 6 C) for quadrants 1e4 at 6.273e mm
[3]þ008  1.599eþ008 mm [3], 1.863eþ009 mm [3]
2.454eþ008 mm [3], 4.252eþ008 mm [3] 3.157eþ008 mm
[3] and 6.837eþ008 mm [3]1.961eþ008 mm [3], respec-
tively. Here, it could be observed that the number of
invasive bodies preliminarily appeared to be in line with
the total volume of cancer growth per quadrant.4. Discussion
In our biomimetic tissue-engineered 3D CRC model, we
were able to demonstrate three novel findings. First, we
were able to obtain comparative observations to the
golden standard of histopathology. Second, we vali-
dated the process of invasive growth as opposed to
migration within our model and how the aggressiveness
of the cancer dictated the rate of this invasion. Third,
the interaction between cancer and the stromal vascular
network response was quantified and validated through
the use of a novel set-up to demonstrate the chemo-
attractant pull between cancer and its vascularised
stroma.
The tumouroid model is relevant in terms of collagen
composition. Some of the most relevant literature
regarding collagen composition in tissues is not new.
Neuman and Logan report the collagen content of
varying tissues. This includes human skin at 72%, rat
skin at 63% and cow tibia at 24%. The rat duodenum
contained 12% collagen (dry weight), which is directly
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10% of this is collagen (also dry weight) [45].
The preinvasive and hence premetastatic clustering of
cancer cells has previously been described as a mecha-
nism regulated by adherent junction protein upregula-
tion. This is associated with the filamentous actin
cytoskeleton causing a tensional force to bring cells
together with limited interstitial space [32] and the
overexpression of EpCAM in gastric cancers [34]. Non-
cancerous colon cells such as CCD 841 CoN have
been used in previous models as a control [22]; however,
their epithelial origin has not been thoroughly validated
(as stated by American type culture collection (ATCC)).
This leads to the possibility that this particular cell line
may be a heterogenous cell population, possibly not
entirely made of colon epithelial cells and therefore not
serving as a good control when comparing with CRC
adenocarcinomas. It is therefore more appropriate that
we refer to them as ‘colon normal cells’ as opposed to
healthy colon epithelial cells. An important observation,
however, was that these ‘normal colon cells’ did not
form 3D cluster aggregates, but remained as single cells
both during the growth phase and the migration phase.
The trend of single cell outgrowth due to spatial limi-
tation and proliferative drive from the central mass into
the stromal compartment was observed in the normal
cells while cancer cells exclusively grew out as cell clus-
ters. This was supported by the overexpression of
MACC1, MMP7 and HPSE genes in our tumouroids.
MACC1 is a marker for advanced CRC [35], whereas
MMP7 is associated with invasive tumour growth and
distant metastasis in CRC [13]. HPSE plays an impor-
tant role in tumour invasion and is associated with poor
prognostic outcomes in gastric cancers [37,46]. There-
fore, the outgrowth in our model can be termed as ‘in-
vasion’ and mimics the invasive growth pattern of CRC
in situ. We have also previously shown that using this
same model, an increase in mRNA expression for
MMP7 was reflected in an increase in the protein
expression for the active form of MMP7 [24].
HCT116 tumouroids showed a more invasive
phenotype in our model, as demonstrated by an increase
in the distance and surface area of invasion into the
stromal compartment compared with other cell lines in
our model. Comparative studies in mice, injected with
the two cell lines, demonstrated that HCT116 cells
would achieve liver metastasis in 100%, whereas
HT29 cells achieved less at 88.9% of samples [47]. It
should be pointed out here that more invasive does not
always mean more metastatic as intact, rounded clusters
are required for successful distant metastases [48].
Within the tumouroid model, HT29 invasive bodies
exhibited this phenotype of rounded intact clusters,
whereas HCT116 grew as thin sheets with frayed edges
and thin protrusions. For observational purposes,
HT29 cells may therefore be more beneficial to use
within the tumouroids as they demonstrate more definedCK20-positive boundaries. While HT29 cells have a p53
mutation, HCT116 ‘tolerate’ the presence of a non-
mutated p53 and overwrite its function [23]. The inher-
ently higher invasive properties of HCT116 CRC cells
were underlined furthermore by the overexpression of
HPSE. This is in line with previous work having
emphasised that HPSE plays a particularly important
role in invasion, metastasis and poor prognosis of
gastric cancers [49,37].
While we observed that endothelial networks forming
further from the ACM (approximately 160 mm) were of
higher complexity than those closer to the ACM, the
other measures were related to vasculogenesis (see
Supplementary Graph 6). However, this indicates an
interesting interplay between cancer and endothelial
cells, which has previously been outlined in the phe-
nomenon of vasculogenic mimicry [50]. As demon-
strated in our data, highly invasive cancers disrupt
vasculature more than less invasive cancers, which is in
direct correlation with the cancer thriving and
attempting not only to obtain a higher oxygen and
nutrient gradient on the outer cell layer consisting of
highly invasive leader cells but also to enter the blood
stream to metastasise [51]. For this work, we used VE-
cadherin as a measure of complexity for the endothelial
networks, a strictly endothelial adhesion molecule that
controls cellular junctions and blood vessel formation
[43]. VE-cadherin was consistently expressed at lower
levels at the gene (see Supplementary Graph 5) and
active protein level for the less invasive CRC. It is for
this reason that the model demonstrates how VE-
cadherin is crucial in vascular complexity. This is a
phenomenon that has been investigated in different
types of cancer as a dysfunction of the molecule [52].
Interestingly, VE-cadherin has also been directly impli-
cated in the extravasation of tumour cells [53], which in
turn would support its lower expression in highly inva-
sive CRC. This naturally would lead to the idea of tar-
geting cancer-induced antagonists of VE-cadherin. The
research on this particular aspect of the cancer cascade
is not particularly uniform, with some groups also
arguing that they have found VE-cadherin to be elevated
in sera of patients with CRC owing to dissociation with
b-catenin complexes [54]. A promising approach has
been seen in directing monoclonal antibodies against
epitopes of VE-cadherin that would disrupt tumour
vasculature but not normal blood vessels [55]. Another
potential drug target we investigated was HGF, which
has been a promising alternative to VEGFA in pancre-
atic cancer [56]. The fact that HGF was highly expressed
in our HCT116 tumouroids validates the level of
measurable biomimicry we can achieve while modelling
CRC.
It is important to note that in these particular ex-
periments, we are investigating overall gene expression
of all cell types within the tumouroid and not necessarily
individual cell populations (‘smoothie vs. fruit salad’
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limitation that a lot of groups are working on surpassing
through, for example, prior cell sorting. Unfortunately,
we are currently not able to extract a single cell type
from our tumouroids when we use cocultures and can
therefore not distinguish which cell type is expressing
which signalling.
Finally, OPT was used for the first time on plastic-
compressed collagen constructs to extract 3D morpho-
logical data from the tumouroids. Although the data
received were limited owing to time constraints, only
allowing for an n Z 1, it was successfully demonstrated
that such an imaging technique could be used on this type
of sample to provide quantitative data. Providing 3D
image data and quantification of a 3D model are vital to
appropriately analyse morphological features. OPT has
largely been used to look at developmental stages of the
mouse embryo and specific target organs of interest. It is
a promising tool to use for large-volume high-resolution
imaging especially in cancer vasculature [58,59].
While there have been great advances in 3D CRC
models recently, our model is able to demonstrate hall-
marks of cancer with a range of invasive and metastatic
properties. We were able to use our platform to create a
high-throughput and novel analysis tool to measure
distance, surface area and volume of invasion. This also
enabled us to answer and validate questions about early
steps of invasion and the important interplay between
cancer and stromal cells, in particular, the tumour
vasculature. Future work could include manipulating
the model further to answer even more focussed ques-
tions such as how the collagen matrix is remodelled
during invasion and what markers are expressed by the
cells during this process. These could then pose as
important potential drug target candidates.
The ultimate personalised healthcare goal would be
to use patient-specific cancer, stromal and immune
cells to recreate patient tumours in vitro. Our model
could be used as a tool to extensively research various
drug treatments on tumours with consideration of the
tumour microenvironment, which a lot of models still
currently lack. Finally, the development of our 3D
model enables hypotheses to be investigated in a struc-
tured and accurate manner with great biomimicry and
the ability to manipulate single variables at a time.Author contributions
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